Cargando…

Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation

OBJECTIVE: Recently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-reject...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yunhui, Liang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598712/
https://www.ncbi.nlm.nih.gov/pubmed/37885888
http://dx.doi.org/10.3389/fimmu.2023.1263389
_version_ 1785125614983839744
author Li, Yunhui
Liang, Bin
author_facet Li, Yunhui
Liang, Bin
author_sort Li, Yunhui
collection PubMed
description OBJECTIVE: Recently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation. METHODS: A systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection. RESULTS: The results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I(2 =) 88.6%, P< 0.001; ACR: SMD=1.03, 95% CI: 0.47-1.59, I(2 =) 89.0%, P < 0.001; AMR: SMD= 1.78, 95% CI: 1.20-2.35, I(2 =) 89.8%, P < 0.001). Circulating dd-cfDNA levels distinguished graft rejection from non-rejection with a pooled sensitivity of 0.87 (95% CI: 0.80-0.92) and a pooled specificity of 0.82 (95% CI: 0.76-0.86). The corresponding SROC yield an AUROC of 0.90 (95% CI: 0.87-0.93). CONCLUSION: Circulating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.
format Online
Article
Text
id pubmed-10598712
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105987122023-10-26 Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation Li, Yunhui Liang, Bin Front Immunol Immunology OBJECTIVE: Recently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation. METHODS: A systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection. RESULTS: The results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I(2 =) 88.6%, P< 0.001; ACR: SMD=1.03, 95% CI: 0.47-1.59, I(2 =) 89.0%, P < 0.001; AMR: SMD= 1.78, 95% CI: 1.20-2.35, I(2 =) 89.8%, P < 0.001). Circulating dd-cfDNA levels distinguished graft rejection from non-rejection with a pooled sensitivity of 0.87 (95% CI: 0.80-0.92) and a pooled specificity of 0.82 (95% CI: 0.76-0.86). The corresponding SROC yield an AUROC of 0.90 (95% CI: 0.87-0.93). CONCLUSION: Circulating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023440467. Frontiers Media S.A. 2023-10-11 /pmc/articles/PMC10598712/ /pubmed/37885888 http://dx.doi.org/10.3389/fimmu.2023.1263389 Text en Copyright © 2023 Li and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Yunhui
Liang, Bin
Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
title Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
title_full Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
title_fullStr Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
title_full_unstemmed Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
title_short Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
title_sort circulating donor-derived cell-free dna as a marker for rejection after lung transplantation
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598712/
https://www.ncbi.nlm.nih.gov/pubmed/37885888
http://dx.doi.org/10.3389/fimmu.2023.1263389
work_keys_str_mv AT liyunhui circulatingdonorderivedcellfreednaasamarkerforrejectionafterlungtransplantation
AT liangbin circulatingdonorderivedcellfreednaasamarkerforrejectionafterlungtransplantation